Last reviewed · How we verify
Human insulin 30/70
Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage.
Human insulin 30/70 is a fixed-ratio combination of 30% short-acting insulin and 70% intermediate-acting insulin that replaces endogenous insulin to regulate blood glucose by promoting cellular glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Human insulin 30/70 |
|---|---|
| Also known as | Human insulin 70/30 (in the United States) |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin, biphasic/fixed-ratio combination |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This biphasic insulin formulation combines rapid-acting insulin (30%) to address postprandial (after-meal) glucose spikes with intermediate-acting insulin (70%) to provide basal glucose control throughout the day. The combination mimics the physiological pattern of endogenous insulin secretion, allowing for once or twice-daily dosing in patients with type 1 and type 2 diabetes who require insulin therapy.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (PHASE1)
- Effect of Insulin Lowering on Lipogenesis (PHASE1)
- ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (PHASE1, PHASE2)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6 (NA)
- Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human insulin 30/70 CI brief — competitive landscape report
- Human insulin 30/70 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI